Work

Dupilumab improves lung function in non-exacerbators with moderate-to-severe COPD with type 2 inflammation in phase 3 BOREAS trial

Year: 2024

Type: conference-abstract

DOI: 10.1183/13993003.congress-2024.pa4785

Authors: Klaus F. Rabe, Claus F. Vogelmeier, Surya P. Bhatt, Nicola A. Hanania, Mona Bafadhel, Stephanie A. Christenson, Alberto Papi, Dave Singh, Elizabeth Laws, Jennifer Maloney, Xin Lu, Deborah Bauer, Ashish Bansal, Lacey B. Robinson, Raolat M. Abdulai

Institutions: German Center for Lung Research, LungenClinic Grosshansdorf, University of Alabama at Birmingham, Baylor College of Medicine, King's College London, University of California, San Francisco, University of Ferrara, University of Manchester, Manchester University NHS Foundation Trust, Sanofi (United States), Regeneron (United States)

Language: English

Topic: Chronic Obstructive Pulmonary Disease (COPD) Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4404096903

Cites:

Cited by: 1

Related to: 10